

High-Level Fosfomycin Resistance in Vancomycin-Resistant *Enterococcus faecium*

Yan Guo, Adam D. Tomich, Christi L. McElheny, Vaughn S. Cooper, Amelia Tait-Kamradt, Minggui Wang, Fupin Hu, Louis B. Rice, Nicolas Sluis-Cremer, Yohei Doi

Of 890 vancomycin-resistant *Enterococcus faecium* isolates obtained by rectal screening from patients in Pittsburgh, Pennsylvania, USA, 4 had MICs >1,024 µg/mL for fosfomycin. These isolates had a Cys119Asp substitution in the active site of UDP-N-acetylglucosamine enolpyruvyl transferase. This substitution increased the fosfomycin MIC \geq 4-fold and rendered this drug inactive in biochemical assays.

Vancomycin-resistant enterococci can cause nosocomial bacteremia, infective endocarditis, and intraabdominal and urinary tract infections that have limited treatment options. Fosfomycin is an antimicrobial drug that shows a wide spectrum of activity that includes enterococci, staphylococci, and many gram-negative species (1). Fosfomycin inactivates UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) by covalent modification of a highly conserved cysteine residue in the active site of MurA (2). Some bacterial species, such as *Borrelia burgdorferi* and *Mycobacterium tuberculosis*, are naturally resistant to fosfomycin because they encode an aspartic acid residue instead of cysteine in the active site of MurA. Furthermore, in *Escherichia coli*, substitution of this cysteine at position 115 by aspartic acid results in fosfomycin resistance (3).

Fosfomycin has historically shown excellent in vitro activity against vancomycin-resistant enterococci, and therefore might be considered as a treatment option for urinary tract infection caused by this organism (4). However, information regarding the activity of fosfomycin against vancomycin-resistant enterococci in the setting of increasing fosfomycin use is limited (5). We tested vancomycin-resistant enterococcal isolates obtained from rectal screening cultures at the University of Pittsburgh Medical Center (Pittsburgh, PA, USA) during 2012–2016 for fosfomycin resistance.

Author affiliations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA (Y. Guo, A.D. Tomich, C.L. McElheny, V.S. Cooper, N. Sluis-Cremer, Y. Doi); Fudan University Huashan Hospital, Shanghai, China (Y. Guo, M. Wang, F. Hu); Brown University, Providence, Rhode Island, USA (A. Tait-Kamradt, L.B. Rice); Fujita Health University, Aichi, Japan (Y. Doi)

DOI: <https://doi.org/10.3201/eid2311.171130>

The Study

We tested 890 vancomycin-resistant enterococcal isolates by growth on Mueller-Hinton agar plates containing 100 or 200 µg/mL fosfomycin and 25 µg/mL glucose-6-phosphate (Sigma-Aldrich, St. Louis, MO, USA). Isolates that grew on both selective plates were subjected to determination of MIC by using the agar dilution method on Mueller-Hinton agar plates supplemented with 25 µg/mL glucose-6-phosphate (6).

Of 234 isolates that grew on fosfomycin-containing selective plates, MICs were 32 µg/mL for 10 (4.3%), 64 µg/mL for 92 (39.3%), 128 µg/mL for 120 (51.3%), 256 µg/mL for 7 (3.0%), 512 µg/mL for 1 (0.4%), and >1,024 µg/mL for 4 (1.7%). When we used the Clinical and Laboratory Standards Institute breakpoint for urinary tract infections (6), we found that 12 isolates (1.3%) had MICs \geq 256 µg/mL and were considered resistant; an additional 120 isolates were considered to have intermediate resistance. The estimated resistance rate of 1.3% is consistent with that reported in a recent surveillance study conducted in the United States (7). However, the resistance rate would be much higher if we applied the European Committee on Antimicrobial Susceptibility Testing (Växjö, Sweden) breakpoint of \leq 32 µg/mL for susceptible isolates and >32 µg/mL for resistant isolates.

The 4 vancomycin-resistant enterococci isolates with MICs >1,024 µg/mL were *Enterococcus faecium*. We subjected these isolates and a representative fosfomycin-susceptible *E. faecium* isolate (kindly provided by L. Harrison) to high-throughput paired-end sequencing by using NextSeq (Illumina, San Diego, CA, USA). We performed de novo assembly by using CLC Genomics Workbench version 10.0 (QIAGEN, Valencia, CA, USA). We deposited assembled genome sequences in GenBank (accession nos. SAMN07274321–5).

The 4 fosfomycin-resistant *E. faecium* isolates belonged to sequence type (ST) 17 (n = 2), ST18 (n = 1), and ST233 (n = 1) on the basis of in silico multilocus sequence typing and all had the *vanA* gene. These STs belong to clonal group 17, which is a prominent hospital-adapted vancomycin-resistant *E. faecium* clonal lineage associated with outbreaks in healthcare environments (8). None of the isolates had *fosB*, a transferable bacillithiol S-transferase gene associated with fosfomycin resistance (9). However, *murA* of the 4 fosfomycin-resistant isolates had a codon change of TGT_{Cys119}→GAT_{Asp119} at nucleotide position 355–357, which was not present in the fosfomycin-susceptible control isolate

or any of the available *E. faecium* genome sequences and was confirmed by Sanger sequencing (online Technical Appendix Figure, <https://wwwnc.cdc.gov/EID/article/23/11/17-1130-Techapp1.pdf>). The *murA* gene of the 8 remaining fosfomycin-resistant isolates with lower MICs of 256 or 512 µg/mL did not contain the nonsynonymous mutations corresponding to C119D. Therefore, the C119D substitution was specific to isolates with a fosfomycin MIC >1,024 µg/mL.

We amplified wild-type and mutant (C119D) *murA*, with their native promoters, by PCR with primers murA-F-*EcoRI* (5'-GAGAGAATTCCATAAAATGAGATGCGGATG-3') and murA-R-*BamHI* (5'-GAGAGGATCCTTAGCAATCGTTTGTGCTG-3') (bold indicates restriction endonuclease site sequences) and cloned them into the shuttle vector pTCV-*lac* (10). We selected *E. coli* TOP10 transformants by using kanamycin and erythromycin. After confirmation of sequences, we transformed recombinant plasmids into *E. coli* SM10, subsequently transferred them into *E. faecium* D344S by conjugation, and performed selection by using kanamycin, fusidic acid, and rifampin. The baseline fosfomycin MIC of the host strain was 128 µg/mL. Introduction of pTCV-*lac-murA*^{WT} resulted in a 4-fold increase in the MIC to 512 µg/mL, which might be caused by increased expression of WT MurA produced as a result of complementation. Nonetheless, introduction of pTCV-*lac-murA*^{C119D} yielded a higher MIC of >1,024 µg/mL, which indicated a ≥4-fold increase in the MIC compared with the *murA*^{WT} control (online Technical Appendix Table). This finding provided phenotypic evidence that C119D MurA is less susceptible to inhibition by fosfomycin.

We determined steady-state Michaelis-Menten parameters for recombinant purified wild-type and C119D MurA (Table; online Technical Appendix). The C119D substitution in MurA increased the mean ± SD Michaelis constant (K_m 803.2 ± 180.0 µmol/L) for UDP-N-acetylglucosamine compared with the wild-type enzyme (K_m 382.8 ± 79.5 µmol/L; $p = 0.02$), but did not affect the catalytic turnover (k_{cat}). This increase in K_m resulted in an ≈2-fold decreased catalytic efficiency (k_{cat}/K_m) for C119D MurA with respect to UDP-N-acetylglucosamine. In contrast, C119D had no major effect on the kinetic parameters for phosphoenolpyruvate as a substrate (Table). The mean ± SD 50% inhibitory concentration of fosfomycin for wild-type MurA was 176.8 ± 38.3 nmol/L; no

inhibition of C119D MurA was observed at concentrations ≤100 µmol/L fosfomycin (Figure).

Our finding that high-level fosfomycin resistance in vancomycin-resistant enterococci can be conferred by substitution of the active site cysteine in MurA is consistent with the mode of action of fosfomycin, which covalently and irreversibly binds to the thiol group of this residue. The MurA enzymes in *M. tuberculosis* and *B. burgdorferi* are refractory to fosfomycin inhibition and naturally possess aspartic acid at the equivalent position (11,12). Previous site-directed mutagenesis-based studies of *E. coli* MurA showed that aspartic acid and glutamic acid substitutions, although conferring fosfomycin resistance, had a major effect on catalytic functioning of the enzyme (3). Specifically, the catalytic efficiency of C115D *E. coli* MurA was reported to be ≥10-fold less than the wild-type enzyme (3).

In our study, the C119D substitution had only minimal effect on vancomycin-resistant enterococci MurA activity. The reason for these differences in kinetic activity is unclear, and additional structure–function studies will be required to elucidate differences between these MurA proteins. Nevertheless, our kinetic data help explain why this substitution was selected in *E. faecium*, whereas *E. coli*–producing C115D MurA has not been identified clinically. The nonsynonymous mutations associated with the C119D substitution of MurA were observed only in isolates that had an MIC >1,024 µg/mL and not in any isolates with lower-level resistance to fosfomycin. Therefore, the mechanisms underlying low-level fosfomycin resistance in enterococci need to be determined.

Conclusions

In this study, fosfomycin maintained activity against most contemporary vancomycin-resistant enterococci isolates, but we identified high-level resistance caused by substitution of the active site cysteine in MurA, which made it refractory to inhibition by fosfomycin but retained its catalytic activity. Our finding that high-level resistance to fosfomycin might arise through mutations of the target enzyme MurA, accompanied by modest impairment of the catalytic activity, indicates the need for ongoing surveillance activities to ensure its activity against vancomycin-resistant enterococci is maintained. In addition, this finding highlights the potential relevance of aspartic

Table. Michaelis-Menten steady-state kinetic parameters for vancomycin-resistant *Enterococcus faecium* wild-type and C119D MurA*

Enzyme	UNAG (p value)				PEP (p value)			
	K_m , µmol/L	V_{max} , µmol/L/min	k_{cat} /min	k_{cat}/K_m , µmol/L/min	K_m , µmol/L	V_{max} , µmol/min	k_{cat} /min	k_{cat}/K_m , µmol/L/min
WT MurA	382.8 ± 79.5	13.9 ± 1.6	138.7 ± 16.4	0.4	229.0 ± 87.201	29.5 ± 8.4	294.5 ± 83.8	1.3
CD119D MurA	803.2 ± 1,780 (0.02)	11.9 ± 2.2 (NS)	119.4 ± 22.2 (NS)	0.2	304.6 ± 35.2 (NS)	28.6 ± 3.2 (NS)	285.5 ± 32.1 (NS)	0.9

*Values are mean ± SD for ≥3 independent experiments unless otherwise indicated. Statistical differences between kinetic parameters for vancomycin-resistant enterococci WT and C119D MurA were assessed by using a paired *t*-test. MurA, UDP-N-acetylglucosamine enolpyruvyl transferase; NS, not significant; PEP, phosphoenolpyruvate; UNAG, UDP-N-acetylglucosamine; WT, wild type.




Figure. Inhibition of recombinant purified vancomycin-resistant *Enterococcus faecium* wild-type (A) and C119D (B) MurA by fosfomycin. The 50% inhibitory concentration was 176.8 ± 38.3 nmol/L for wild-type MurA and >100 μmol/L for C119D MurA. Error bars indicate mean \pm SD of ≥ 3 independent experiments. MurA, UDP-N-acetylglucosamine enolpyruvyl transferase.

acid-substituted, catalytically active MurA enzymes as a target for inhibitor development.

Acknowledgment

We thank Lee Harrison for providing vancomycin-resistant *E. faecium* isolates used in this study.

Y.D. was supported by grants from the National Institutes of Health (R01AI104895 and R21AI123747).

Dr. Guo is a visiting researcher in the Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, PA. Her research interests include mechanisms of multidrug resistance in gram-positive bacteria.

References

1. Sastry S, Doi Y. Fosfomycin: resurgence of an old companion. *J Infect Chemother.* 2016;22:273–80. <http://dx.doi.org/10.1016/j.jiac.2016.01.010>
2. Eschenburg S, Priestman M, Schönbrunn E. Evidence that the fosfomycin target Cys115 in UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) is essential for product release. *J Biol Chem.* 2005;280:3757–63. <http://dx.doi.org/10.1074/jbc.M411325200>
3. Kim DH, Lees WJ, Kempell KE, Lane WS, Duncan K, Walsh CT. Characterization of a Cys115 to Asp substitution in the *Escherichia coli* cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that confers resistance to inactivation by the antibiotic fosfomycin. *Biochemistry.* 1996;35:4923–8. <http://dx.doi.org/10.1021/bi952937w>
4. Sastry S, Clarke LG, Alrowais H, Querry AM, Shutt KA, Doi Y. Clinical appraisal of fosfomycin in the era of antimicrobial resistance. *Antimicrob Agents Chemother.* 2015;59:7355–61. <http://dx.doi.org/10.1128/AAC.01071-15>
5. Falagas ME, Roussos N, Gkegkes ID, Rafailidis PI, Karageorgopoulos DE. Fosfomycin for the treatment of infections caused by gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. *Expert Opin Investig Drugs.* 2009;18:921–44. <http://dx.doi.org/10.1517/13543780902967624>
6. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 27th edition (M100–S27). Wayne (PA): The Institute; 2017.
7. Keepers TR, Gomez M, Celeri C, Krause KM, Biek D, Critchley I. Fosfomycin and comparator activity against select *Enterobacteriaceae*, *Pseudomonas*, and *Enterococcus* urinary tract infection isolates from the United States in 2012. *Infect Dis Ther.* 2017;6:233–43. <http://dx.doi.org/10.1007/s40121-017-0150-5>
8. Cattoir V, Leclercq R. Twenty-five years of shared life with vancomycin-resistant enterococci: is it time to divorce? *J Antimicrob Chemother.* 2013;68:731–42. <http://dx.doi.org/10.1093/jac/dks469>
9. Xu X, Chen C, Lin D, Guo Q, Hu F, Zhu D, et al. The fosfomycin resistance gene *fosB3* is located on a transferable, extrachromosomal circular intermediate in clinical *Enterococcus faecium* isolates. *PLoS One.* 2013;8:e78106. <http://dx.doi.org/10.1371/journal.pone.0078106>
10. Poyart C, Trieu-Cuot P. A broad-host-range mobilizable shuttle vector for the construction of transcriptional fusions to beta-galactosidase in gram-positive bacteria. *FEMS Microbiol Lett.* 1997;156:193–8. [http://dx.doi.org/10.1016/S0378-1097\(97\)00423-0](http://dx.doi.org/10.1016/S0378-1097(97)00423-0)
11. De Smet KA, Kempell KE, Gallagher A, Duncan K, Young DB. Alteration of a single amino acid residue reverses fosfomycin resistance of recombinant MurA from *Mycobacterium tuberculosis*. *Microbiology.* 1999;145:3177–84. <http://dx.doi.org/10.1099/00221287-145-11-3177>
12. Jiang S, Gilpin ME, Attia M, Ting YL, Berti PJ. Lyme disease enolpyruvyl-UDP-GlcNAc synthase: fosfomycin-resistant MurA from *Borrelia burgdorferi*, a fosfomycin-sensitive mutant, and the catalytic role of the active site Asp. *Biochemistry.* 2011;50:2205–12. <http://dx.doi.org/10.1021/bi1017842>

Address for correspondence: Yohei Doi, Division of Infectious Diseases, University of Pittsburgh Medical Center, S829 Scaife Hall, 3550 Terrace St, Pittsburgh, PA 15261, USA; email: yod4@pitt.edu

High-Level Fosfomycin Resistance in Vancomycin-Resistant *Enterococcus faecium*

Technical Appendix

Supplementary Methods

Cloning and Purification of MurA

Wild-type and C119D UDP-N-acetylglucosamine enolpyruvyl transferase (*murA*) genes were synthesized (Genscript, Piscataway, NJ, USA), cloned into the pE-SUMOstar prokaryotic expression vector (LifeSensors, Malvern, PA, USA), and transformed into *Escherichia coli* BL21 (DE3) pLysS competent cells (Promega, Madison, WI, USA). Transformed *E. coli* BL21 (DE3) were grown overnight at 37°C in Power Prime Broth (AthenaES, Baltimore, MD, USA) containing 100 mg/L of ampicillin. Overnight cultures were diluted 1:50 in fresh Power Prime Broth, grown to midlog phase (optical density = 0.3 at 600 nm), before protein expression was induced for 4 h at 37°C by addition of 1 mmol/L isopropyl β-D-1-thiogalactopyranoside. Cells were harvested by centrifugation, suspended in 50 mmol/L sodium phosphate buffer (pH 7.8) containing protease inhibitor (lysis buffer), and lysed by using a French press.

Cell supernatants were mixed with prepared TALON Metal Affinity Resin (Clontech Laboratories, Inc., Mountain View, CA, USA), loaded onto a gravity-flow column, and washed with 50 mmol/L sodium phosphate (pH 7.8) containing 0.3 mol/L NaCl and 1 mmol/L β-mercaptoethanol. Bound protein was eluted with 100 mmol/L sodium phosphate (pH 6.0) containing 0.6 mol/L NaCl, 240 mmol/L imidazole, and 1 mmol/L β-mercaptoethanol. The protein was then exchanged into 25 mmol/L Tris-HCl (pH 7.5) by using an NAP-25 column (GE Healthcare, Chicago, IL, USA). Protein concentration was determined by using a Bradford assay with bovine serum albumin as the standard. Purity was assessed by using sodium dodecyl sulfate–polyacrylamide gel electrophoresis. Purified proteins were stored in 25% glycerol at –80°C.

MurA Steady-State Kinetic Assays

MurA (100 nmol/L) was incubated with various concentrations of UDP-N-acetylglucosamine (UNAG) (0–3 mmol/L) or phosphoenolpyruvate (PEP) (0–1 mmol/L) in 50 mmol/L Tris-HCl buffer (pH 7.5) at 37°C for 10 min. Reactions were initiated with 300 μmol/L PEP (for various concentrations of UNAG) or 3 mmol/L UNAG (for various concentrations of PEP) at 37°C for 20 min. Reactions were then quenched, and inorganic phosphate was quantified by using the Malachite Green Phosphate Assay Kit, (BioAssay Systems, Hayward, CA, USA) per the manufacturer’s recommendations. Data were fitted to Michaelis-Menten equations by using GraphPad Prism version 6 (GraphPad Software, San Diego, CA, USA).

Fosfomycin Inhibition Assay

For inhibition assays, 100 nmol/L of wild-type or mutant MurA was incubated with various concentrations of fosfomycin and 3 mmol/L UNAG at 37°C for 10 min. Reactions were initiated with 300 μmol/L PEP, and inorganic phosphate was quantified as described. The concentration of fosfomycin that resulted in 50% inhibition was determined by using GraphPad Prism version 6.

Technical Appendix Table. Characteristics of strains and plasmids used in the study of high-level fosfomycin resistance in vancomycin-resistant *Enterococcus faecium**

Strain or plasmid	Fosfomycin MIC, mg/L	Description/use
Clinical strain		
<i>Enterococcus faecium</i> 2014–7	>1,024	<i>murA</i> ^{C119D}
<i>E. faecium</i> 2014–195	>1,024	<i>murA</i> ^{C119D}
<i>E. faecium</i> 2015–149	>1,024	<i>murA</i> ^{C119D}
<i>E. faecium</i> 2016–78	>1,024	<i>murA</i> ^{C119D}
<i>E. faecium</i> 2016–194	64	<i>murA</i> ^{WT}
Transformant		
<i>E. faecium</i> D344S (pTCV-lac ^{C119D})	>1,024	<i>murA</i> ^{C119D}
<i>E. faecium</i> D344S (pTCV-lac ^{WT})	512	<i>murA</i> ^{WT}
<i>E. faecium</i> D344S (pTCV-lac)	128	Control
Host strain		
<i>E. faecium</i> D344S	NA	NA
<i>Escherichia coli</i> SM10	NA	Plasmid transfer
<i>E. coli</i> TOP10	NA	Plasmid transfer
<i>E. coli</i> BL21 (DE3)	NA	Protein expression
Plasmid		
pTCV-lac	NA	NA
pE-SUMOstar	NA	Cloning of <i>murA</i> ; erythromycin and kanamycin resistant Expression of <i>murA</i> ; ampicillin resistant

*murA, UDP-N-acetylglucosamine enolpyruvyl transferase; NA, not applicable; WT, wild type.


```

MurA_2014-7      MEEIIVRGGNQLNGTVRIEGAKNAVLPILAASLLAEEGITTLDNVPILSDVFTMNQVIRH 60
MurA_2014-195   MEEIIVRGGNQLNGTVRIEGAKNAVLPILAASLLAEEGITTLDNVPILSDVFTMNQVIRH
MurA_2015-149   MEEIIVRGGNQLNGTVRIEGAKNAVLPILAASLLAEEGITTLDNVPILSDVFTMNQVIRH
MurA_2016-78    MEEIIVRGGNQLNGTVRIEGAKNAVLPILAASLLAEEGITTLDNVPILSDVFTMNQVIRH
MurA_2016-194   MEEIIVRGGNQLNGTVRIEGAKNAVLPILAASLLAEEGITTLDNVPILSDVFTMNQVIRH
MurA_consensus  MEEIIVRGGNQLNGTVRIEGAKNAVLPILAASLLAEEGITTLDNVPILSDVFTMNQVIRH
*****

MurA_2014-7      LNVVDVDFDEQKNQVTIDASRQLEIEAPYEYVSQMRASIVVMGPLLARNGHAKVAMPGGDA 120
MurA_2014-195   LNVVDVDFDEQKNQVTIDASRQLEIEAPYEYVSQMRASIVVMGPLLARNGHAKVAMPGGDA
MurA_2015-149   LNVVDVDFDEQKNQVTIDASRQLEIEAPYEYVSQMRASIVVMGPLLARNGHAKVAMPGGDA
MurA_2016-78    LNVVDVDFDEQKNQVTIDASRQLEIEAPYEYVSQMRASIVVMGPLLARNGHAKVAMPGGDA
MurA_2016-194   LNVVDVDFDEQKNQVTIDASRQLEIEAPYEYVSQMRASIVVMGPLLARNGHAKVAMPGGDA
MurA_consensus  LNVVDVDFDEQKNQVTIDASRQLEIEAPYEYVSQMRASIVVMGPLLARNGHAKVAMPGGDA
*****

MurA_2014-7      IGKRPIDLHLKGFQALGAKIIQKNGYIEAIADELIGNTIYLDFFPSVGATQNIMMAAVKAK 180
MurA_2014-195   IGKRPIDLHLKGFQALGAKIIQKNGYIEAIADELIGNTIYLDFFPSVGATQNIMMAAVKAK
MurA_2015-149   IGKRPIDLHLKGFQALGAKIIQKNGYIEAIADELIGNTIYLDFFPSVGATQNIMMAAVKAK
MurA_2016-78    IGKRPIDLHLKGFQALGAKIIQKNGYIEAIADELIGNTIYLDFFPSVGATQNIMMAAVKAK
MurA_2016-194   IGKRPIDLHLKGFQALGAKIIQKNGYIEAIADELIGNTIYLDFFPSVGATQNIMMAAVKAK
MurA_consensus  IGKRPIDLHLKGFQALGAKIIQKNGYIEAIADELIGNTIYLDFFPSVGATQNIMMAAVKAK
*****

MurA_2014-7      GTTIIENVAREPEIVDLANILNKMGAVQYVAGTETMRIEGVDHLHAVNHSIVQDRIEAGT 240
MurA_2014-195   GTTIIENVAREPEIVDLANILNKMGAVQYVAGTETMRIEGVDHLHAVNHSIVQDRIEAGT
MurA_2015-149   GTTIIENVAREPEIVDLANILNKMGAVQYVAGTETMRIEGVDHLHAVNHSIVQDRIEAGT
MurA_2016-78    GTTIIENVAREPEIVDLANILNKMGAVQYVAGTETMRIEGVDHLHAVNHSIVQDRIEAGT
MurA_2016-194   GTTIIENVAREPEIVDLANILNKMGAVQYVAGTETMRIEGVDHLHAVNHSIVQDRIEAGT
MurA_consensus  GTTIIENVAREPEIVDLANILNKMGAVQYVAGTETMRIEGVDHLHAVNHSIVQDRIEAGT
*****

MurA_2014-7      FMVAAAMTQGNVLIADAISEHNRPLISKLIEMGAEIEEEGGVVRVIGPKHILPTDVKTMP 300
MurA_2014-195   FMVAAAMTQGNVLIADAISEHNRPLISKLIEMGAEIEEEGGVVRVIGPKHILPTDVKTMP
MurA_2015-149   FMVAAAMTQGNVLIADAISEHNRPLISKLIEMGAEIEEEGGVVRVIGPKHILPTDVKTMP
MurA_2016-78    FMVAAAMTQGNVLIADAISEHNRPLISKLIEMGAEIEEEGGVVRVIGPKHILPTDVKTMP
MurA_2016-194   FMVAAAMTQGNVLIADAISEHNRPLISKLIEMGAEIEEEGGVVRVIGPKHILPTDVKTMP
MurA_consensus  FMVAAAMTQGNVLIADAISEHNRPLISKLIEMGAEIEEEGGVVRVIGPKHILPTDVKTMP
*****

MurA_2014-7      HPGFPDMQAQMTAIQLVAEGTSVVTETVFENRFQHLEEMRRMNAHVKIDGNVAIMDGNH 360
MurA_2014-195   HPGFPDMQAQMTAIQLVAEGTSVVTETVFENRFQHLEEMRRMNAHVKIDGNVAIMDGNH
MurA_2015-149   HPGFPDMQAQMTAIQLVAEGTSVVTETVFENRFQHLEEMRRMNAHVKIDGNVAIMDGNH
MurA_2016-78    HPGFPDMQAQMTAIQLVAEGTSVVTETVFENRFQHLEEMRRMNAHVKIDGNVAIMDGNH
MurA_2016-194   HPGFPDMQAQMTAIQLVAEGTSVVTETVFENRFQHLEEMRRMNAHVKIDGNVAIMDGNH
MurA_consensus  HPGFPDMQAQMTAIQLVAEGTSVVTETVFENRFQHLEEMRRMNAHVKIDGNVAIMDGNH
*****

MurA_2014-7      ELQGAEVYATDLRAAAALVLAGLKANGITRVRNLNYLDRGYNFHIIKLQQLGADVERVDM 420
MurA_2014-195   ELQGAEVYATDLRAAAALVLAGLKANGITRVRNLNYLDRGYNFHIIKLQQLGADVERVDM
MurA_2015-149   ELQGAEVYATDLRAAAALVLAGLKANGITRVRNLNYLDRGYNFHIIKLQQLGADVERVDM
MurA_2016-78    ELQGAEVYATDLRAAAALVLAGLKANGITRVRNLNYLDRGYNFHIIKLQQLGADVERVDM
MurA_2016-194   ELQGAEVYATDLRAAAALVLAGLKANGITRVRNLNYLDRGYNFHIIKLQQLGADVERVDM
MurA_consensus  ELQGAEVYATDLRAAAALVLAGLKANGITRVRNLNYLDRGYNFHIIKLQQLGADVERVDM
*****

MurA_2014-7      DQTSAEKTAQTIA 433
MurA_2014-195   DQTSAEKTAQTIA
MurA_2015-149   DQTSAEKTAQTIA
MurA_2016-78    DQTSAEKTAQTIA
MurA_2016-194   DQTSAEKTAQTIA
MurA_consensus  DQTSAEKTAQTIA
*****

```

Technical Appendix Figure. Alignment of the deduced amino acid sequences of wild type and C119D UDP-N-acetylglucosamine enolpyruvyl transferase. (MurA) of vancomycin-resistant *E. faecium* isolates. Strains 2014–7, 2014–195, 2015–149, and 2016–78 have fosfomycin MICs >1,024 mg/L. Strain 2016–194 has a fosfomycin MIC of 64 mg/L. The consensus sequence is derived from WP_002289003.1 and represents the MurA sequence of 450 *E. faecium* strains available in GenBank. Box indicates change from cysteine to aspartic acid at position 119. Asterisks indicate identity at each position.